|
KMID : 0191120130280050750
|
|
Journal of Korean Medical Science
2013 Volume.28 No. 5 p.750 ~ p.754
|
|
|
Clinical Usefulness of Plasma Chromogranin A in Pancreatic Neuroendocrine Neoplasm
|
|
Paik Woo-Hyun
Ryu Ji-Kon
Song Byeong-Jun
Kim Jai-Hwan
Park Joo-Kyung
Kim Yong-Tae
Yoon Yong-Bum
|
|
|
Abstract
|
|
|
|
Chromogranin A (CgA) is widely used as an immunohistochemical marker of neuroendocrine neoplasms and has been measurable in plasma of patients. We assessed the clinical role of plasma CgA in diagnosing pancreatic neuroendocrine neoplasm (PNEN). CgA was checked in 44 patients with pancreatic mass who underwent surgical resection from 2009 through 2011. The cutoff value for diagnosing PNEN and the relationships between CgA and clinicopathologic variables were analyzed. Twenty-six patients were PNENs and 18 patients were other pancreatic disorders. ROC analysis showed a cutoff of 60.7 ng/mL with 77% sensitivity and 56% specificity, and the area under the curve (AUC) was 0.679. Among PNEN group, the sensitivity and specificity of diagnosing metastasis were 100% and 90% respectively when CgA cutoff was 156.5 ng/mL. The AUC was 0.958. High Ki-67 index (160.8 vs 62.1 ng/mL, P = 0.001) and mitotic count (173.5 vs 74.6 ng/mL, P = 0.044) were significantly correlated with plasma CgA, but the tumor size was not. In conclusion, CgA has a little value in diagnosing PNEN. However, the high level of CgA (more than 156.5 ng/mL) can predict the metastasis. Also, plasma CgA level correlates with Ki-67 index and mitotic count which represents prognosis of PNENs
|
|
|
KEYWORD
|
|
|
Pancreatic Neuroendocrine Neoplasm, Chromogranin A, Diagnosis, Pancreatic Neoplasms
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|